(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
3 days till quarter result
(amc 2024-05-07)
Expected move: +/- 6.15%
0.79% $ 20.35
@ $25.39
Emitido: 14 feb 2024 @ 15:49
Retorno: -19.85%
Señal anterior: feb 14 - 09:30
Señal anterior:
Retorno: 3.63 %
Live Chart Being Loaded With Signals
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis...
Stats | |
---|---|
Volumen de hoy | 444 362 |
Volumen promedio | 689 075 |
Capitalización de mercado | 1.53B |
EPS | $0 ( 2024-05-02 ) |
Próxima fecha de ganancias | ( $-0.190 ) 2024-05-07 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -19.95 |
ATR14 | $0.0110 (0.05%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-01 | Eastham Karin | Buy | 10 000 | Common Stock |
2024-04-01 | Eastham Karin | Sell | 10 000 | Common Stock |
2024-04-01 | Eastham Karin | Sell | 10 000 | Stock Option (right to buy) |
2024-03-15 | Chambers Rebecca | Buy | 4 318 | Common Stock |
2024-03-15 | Chambers Rebecca | Sell | 2 189 | Common Stock |
INSIDER POWER |
---|
32.67 |
Last 99 transactions |
Buy: 1 146 076 | Sell: 688 515 |
Volumen Correlación
Veracyte Inc Correlación
10 Correlaciones Más Positivas | |
---|---|
SPTN | 0.949 |
VORB | 0.945 |
SSTI | 0.943 |
AKAN | 0.941 |
APPS | 0.94 |
MMAC | 0.939 |
AGRX | 0.938 |
PEAR | 0.938 |
BNRG | 0.937 |
LPSN | 0.937 |
10 Correlaciones Más Negativas | |
---|---|
GXII | -0.965 |
TBSAU | -0.958 |
AGGR | -0.958 |
RMRM | -0.957 |
HERA | -0.955 |
SCOB | -0.953 |
LGAC | -0.953 |
NVSA | -0.953 |
AEAC | -0.953 |
CRZN | -0.952 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Veracyte Inc Correlación - Moneda/Commodity
Veracyte Inc Finanzas
Annual | 2023 |
Ingresos: | $361.05M |
Beneficio Bruto: | $223.15M (61.81 %) |
EPS: | $-1.020 |
FY | 2023 |
Ingresos: | $361.05M |
Beneficio Bruto: | $223.15M (61.81 %) |
EPS: | $-1.020 |
FY | 2022 |
Ingresos: | $296.54M |
Beneficio Bruto: | $194.95M (65.74 %) |
EPS: | $-0.510 |
FY | 2021 |
Ingresos: | $219.51M |
Beneficio Bruto: | $145.11M (66.11 %) |
EPS: | $-1.419 |
Financial Reports:
No articles found.
Veracyte Inc
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis. It is also developing Percepta Genomic Atlas to help inform lung cancer treatment decisions; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has technology licensing and collaboration arrangements with Johnson & Johnson; Acerta Pharma; and CareDx. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico